Literature DB >> 32034420

Detection of Variants With Reduced Baloxavir Marboxil Susceptibility After Treatment of Children With Influenza A During the 2018-2019 Influenza Season.

Masatoki Sato1, Emi Takashita2, Masahiko Katayose3, Kenji Nemoto4, Nobuko Sakai5, Koichi Hashimoto1, Mitsuaki Hosoya1.   

Abstract

During the 2018-2019 influenza seasons, we detected reduced baloxavir marboxil (baloxavir) susceptible variants with I38S or I38T amino acid substitutions on the PA subunit of influenza virus ribonucleic acid polymerase in 7 of 18 baloxavi-treated children and found that virus titer rebounded in some of these children with variants. We also found fever durations to be similar between patients with or without the variants, but the patients with variants shed the virus 3 days longer and took longer to improve clinical symptoms than those without variants. The emergence of these variants should be monitored during future influenza seasons.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antiviral therapy; baloxavir; influenza; oseltamivir; resistance

Mesh:

Substances:

Year:  2020        PMID: 32034420     DOI: 10.1093/infdis/jiaa061

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Postexposure Liponucleotide Prophylaxis and Treatment Attenuates Acute Respiratory Distress Syndrome in Influenza-infected Mice.

Authors:  Lucia E Rosas; Lauren M Doolittle; Lisa M Joseph; Hasan El-Musa; Michael V Novotny; Judy M Hickman-Davis; R Duncan Hite; Ian C Davis
Journal:  Am J Respir Cell Mol Biol       Date:  2021-06       Impact factor: 6.914

2.  Vigna radiata (L.) R. Wilczek Extract Inhibits Influenza A Virus by Targeting Viral Attachment, Penetration, Assembly, and Release.

Authors:  Chieh-Wen Lo; Chia-Chen Pi; You-Ting Chen; Hui-Wen Chen
Journal:  Front Pharmacol       Date:  2020-11-26       Impact factor: 5.810

3.  CRISPR-Cas3-based diagnostics for SARS-CoV-2 and influenza virus.

Authors:  Kazuto Yoshimi; Kohei Takeshita; Seiya Yamayoshi; Satomi Shibumura; Yuko Yamauchi; Masaki Yamamoto; Hiroshi Yotsuyanagi; Yoshihiro Kawaoka; Tomoji Mashimo
Journal:  iScience       Date:  2022-01-30

Review 4.  Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group.

Authors:  Michael G Ison; Frederick G Hayden; Alan J Hay; Larisa V Gubareva; Elena A Govorkova; Emi Takashita; Jennifer L McKimm-Breschkin
Journal:  Antiviral Res       Date:  2021-08-04       Impact factor: 10.103

5.  Comprehensive assessment of amino acid substitutions in the trimeric RNA polymerase complex of influenza A virus detected in clinical trials of baloxavir marboxil.

Authors:  Takashi Hashimoto; Keiko Baba; Kae Inoue; Miyako Okane; Satoshi Hata; Takao Shishido; Akira Naito; Steffen Wildum; Shinya Omoto
Journal:  Influenza Other Respir Viruses       Date:  2020-10-24       Impact factor: 4.380

Review 6.  Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice.

Authors:  Sara Scarpini; Francesca Morigi; Ludovica Betti; Arianna Dondi; Carlotta Biagi; Marcello Lanari
Journal:  Vaccines (Basel)       Date:  2021-05-25

Review 7.  Baloxavir Marboxil: An Original New Drug against Influenza.

Authors:  François Dufrasne
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.